Indacaterol (Arcapta Neohaler) for chronic obstructive pulmonary disease

P and T

Volumn 37, Issue 2, 2012, Pages 86-98

  Slaton, Rachel M ^a   Cruthirds, Danielle L ^a  

^a SAMFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARFORMOTEROL; CORTICOSTEROID; CYCLIC AMP; FORMOTEROL; FORMOTEROL FUMARATE; INDACATEROL; SALMETEROL; SALMETEROL XINAFOATE;

AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE;

EID: 84857148531     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Williams DM, Bourdet SV. Chronic obstructive pulmonary disease. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: A Pathophysiologic Approach, 8th ed. New York: McGraw-Hill; 2011:439-464.
2. Akinbami LJ, Liu X. Chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998-2009. NCHS Data Brief 2011; No. 63:1-8. Available at www.cdc.gov/nchs/data/databriefs/db63.htm. Accessed September 26, 2011.
3. Miniño AM. Death in the United States, 2009. NCHS Data Brief 2011;64:1-8. Available at www.cdc.gov/nchsdata/databriefs/db64.htm. Accessed September 26, 2011.
4. Reilly JJ Jr, Silverman EK, Shapiro SD, et al. Chronic obstructive pulmonary disease. In: Longo DL, Fauci AS, Kasper DL, et al., eds. Harrison's Principles of Internal Medicine, 18th ed, chap 260. New York: McGraw-Hill; 2011. Available at: www.accesspharmacy.com/content.aspx?aID=9128463. Accessed September 26, 2011.
5. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-191.
6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2010). Available at: www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf. Accessed September 30, 2011.
7. Indacaterol. In: Facts and Comparisons. St. Louis, Mo.: Wolters Kluwer Health. Updated July 2011. Available at: http://online.factsandcomparisons.com.ezproxy.samford.edu. Accessed September 27, 2011.
8. TM (indacaterol inhalation powder), prescribing information. East Hanover, N.J.: Novartis; July 2011. Available at: www.pharma.us.novartis.com/product/pi/pdf/arcapta.pdf. Accessed July 15, 2011.
9. Red Book® Online. Greenwood Village, Colo.: Thomson Healthcare; 2011. Available at: www.redbook.com/redbook/online. Accessed September 27, 2011.
10. Roig J, Hernando R, Mora R. Indacaterol, a novel once daily inhaled beta2-adreno receptor agonist. Open Respir Med J 2009; 3:27-30.
11. Chowdhury BA. Summary Review of Regulatory Action. FDA, Center for Drug Evaluation and Research. Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000MedR.pdf. Accessed August 30, 2011.
12. Beeh K, Beier J. Indacaterol: A new once daily long-acting beta2-adrenoreceptor agonist. Core Evid 2009:4:37-41.
13. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 mcg once daily in COPD: A double-blind, randomised, 12-week study. BMC Pulm Med 2010;10:11.
14. Jones P, Barnes N, Vogelmeier C, et al. Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J 2011;20(4):380-388.
15. Assessment Report for Onbrez Breezhaler. London, U.K.: European Medicines Agency (EMA); December 2009. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001114/WC500053735.pdf. Accessed September 27, 2011.
16. Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with COPD: A 28-day randomized, placebo controlled clinical trial. Pulm Pharmacol Ther 2007;20:740-749.
17. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tio-tro pium comparison. Respir Med 2008; 102(7):1033-1044.
18. Kato M, Makita H, Uemura K, et al. Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial. Allergol Int 2010; 59(3):285-293.
19. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010;23(3):165-171.
20. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twicedaily formoterol in COPD. Thorax 2010; 65(6):473-479.
21. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: Indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182(2):155-162.
22. Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a novel long-acting beta2-agonist, in subjects with COPD: A randomized, placebo-controlled study. Chest 2011; 140(1):68-75.
23. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twicedaily salmeterol for COPD: A placebocontrolled comparison. Eur Respir J 2011; 37(2):273-279.
24. Balint B, Watz H, Amos C, et al. Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 2010;5:311-318.
25. Korn S, Kerwin E, Atis S, et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study. Respir Med 2011;105(5): 719-726.
26. Beier J, Beeh KM, Brookman L, et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009;22(6):492-496.
27. Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterol provides 24-hour bronchodilation in COPD: A placebocontrolled blinded comparison with tiotropium. Respir Res 2010;11:135 (online).
28. Magnussen H, Verkindre C, Jack D, et al. Indacaterol once daily is equally effective dosed in the evening or morning in COPD. Respir Med 2010;104(12):1869-1876.
29. Laforce C, Aumann J, de Teresa Parreño L, et al. Sustained 24-hour efficacy of once daily indacaterol (300 mcg) in patients with chronic obstructive pulmonary disease: A randomized, crossover study. Pulm Pharmacol Ther 2011;24(1):162-168.
30. O'Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011;105:1030-1036.
31. Serevent® Diskus® (salmeterol xinafoate inhalation powder), prescribing information. Research Triangle Park, N.C.: GlaxoSmithKline; April 2011. Available at: http://us.gsk.com/products/assets/us_serevent_diskus.pdf. Accessed June 15, 2011.
32. Foradil® Aerolizer® (formoterol fumarate inhalation powder), prescribing information. Whitehouse Station, N.J.: Merck & Co.; May 2011. Available at: www.spfiles.com/piforadil.pdf. Accessed June 15, 2011.
33. Brovana® (arformoterol tartrate) Inhalation Solution, prescribing information. Marlborough, Mass.: Sunovion; January 2011. Available at: www.brovana.com/BrovanaApprovedLabelingText.pdf. Accessed June 15, 2011.
34. Barrons R, Pegram A, Borries A. Inhaler device selection: Special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm 2011;68:1221-1232.
35. Hui CK, Chung KF. Indacaterol: Pharmacologic profile, efficacy, and safety in the treatment of adults with COPD. Exp Rev Respir Med 2011;5(1):9-16.
36. Khindri S, Sabo R, Harris S, et al. Cardiac safety of indacaterol in healthy subjects: A randomized, multidose, placebo and positive-controlled, parallel-group thorough QT study. BMC Pulm Med 2011; 11:31(online).
37. Worth H, Chung KF, Kelser JM, et al. Cardio- and cerebrovascular safety of indacaterol vs. formoterol, salmeterol, tiotropium, and placebo in COPD. Respir Med 2011;105(4):571-579.